Does Lacosamide Raise or Lower Blood Pressure?
Lacosamide, an anticonvulsant used for partial-onset seizures, has minimal direct effects on blood pressure in most patients. Clinical trials and post-marketing data show no consistent hypertensive or hypotensive impact at standard doses (200-400 mg/day). However, rare cases of hypertension have been reported, with incidence under 1%.[1][2]
What Do Clinical Studies Show?
In pivotal trials like SP667 (n=485), mean systolic blood pressure changed by less than 1 mmHg from baseline, with no significant group differences versus placebo. Similar results appear in long-term extension studies (up to 8 years), where blood pressure fluctuations aligned with age-related norms rather than drug effects. Orthostatic hypotension is not a noted risk, unlike some older antiepileptics.[1][3]
Are There Reports of Hypertension or Hypotension?
Adverse event databases log hypertension in 0.5-1.2% of users, often transient and linked to high doses (>600 mg/day) or IV administration. Hypotension occurs even less frequently (<0.5%), typically during rapid IV infusion causing PR interval prolongation or bradycardia. These resolve with dose adjustment or slower infusion.[2][4]
Who Might Experience Blood Pressure Changes?
Patients with preexisting cardiovascular conditions, the elderly, or those on interacting drugs (e.g., beta-blockers, antihypertensives) report changes more often. Pediatric data is limited but shows similar low rates. No causal link to cardiogenic shock or sustained hypertension exists.[1][5]
How Does It Compare to Other Antiepileptics?
Unlike carbamazepine or phenytoin, which can induce hypertension via sodium retention, lacosamide's mechanism (slowed sodium channel inactivation) spares hemodynamic effects. It resembles levetiracetam more closely, with neutral cardiovascular profile.[3][6]
[1]: Vimpat (lacosamide) Prescribing Information, UCB, 2023. https://www.vimpat.com/
[2]: FDA Adverse Event Reporting System (FAERS) summary for lacosamide, 2023. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files/
[3]: Biton et al., "Long-term safety of lacosamide," Epilepsia, 2012. https://pubmed.ncbi.nlm.nih.gov/23087344/
[4]: ClinicalTrials.gov, NCT00767965 (SP667 trial results). https://clinicaltrials.gov/study/NCT00767965
[5]: European Medicines Agency (EMA) Vimpat Summary of Product Characteristics, 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat
[6]: Harden et al., "Practice parameter: Antiepileptic drugs and cardiovascular risk," Neurology, 2014. https://pubmed.ncbi.nlm.nih.gov/24523484/